ETC
ACRV icon

Exchange Traded Concepts’s Acrivon Therapeutics ACRV Stock Holding History

Exchange Traded Concepts’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,161
Closed -$47K – 1408
2025
Q1 		$47K Buy
23,161
+2,813
+14% +$15.1K ﹤0.01% 1233
2024
Q4 		$122K Hold
20,348
– – ﹤0.01% 1110
2024
Q3 		$142K Sell
20,348
-22,516
-53% -$177K ﹤0.01% 1081
2024
Q2 		$249K Sell
42,864
-13,336
-24% -$107K 0.01% 845
2024
Q1 		$402K Buy
56,200
+42,911
+323% +$199K 0.01% 679
2023
Q4 		$65.4K Buy
13,289
+3,370
+34% +$17.8K ﹤0.01% 923
2023
Q3 		$94.8K Sell
9,919
-1,790
-15% -$20.7K ﹤0.01% 916
2023
Q2 		$152K Buy
+11,709
New +$142K ﹤0.01% 836

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Exchange Traded Concepts's ACRV Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 23,161 shares — an estimated $47K sold.

Exchange Traded Concepts first reported a position in ACRV in Q2 2023 and held it in 8 quarters. The position peaked at $402K in Q1 2024. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 23,161 Acrivon Therapeutics shares in Q2 2025, an estimated $47K.
  • Exchange Traded Concepts first reported a position in Acrivon Therapeutics in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Acrivon Therapeutics position peaked at $402K in Q1 2024.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.